PS
BBIO icon

Principal Securities’s BridgeBio Pharma BBIO Stock Holding History

Principal Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$831 – 1547
2025
Q3 		$831 Sell
16
-22
-58% -$1.07K ﹤0.01% 3445
2025
Q2 		$1.64K Hold
38
– – ﹤0.01% 3206
2025
Q1 		$1.04K Hold
38
– – ﹤0.01% 3201
2024
Q4 		$1.04K Hold
38
– – ﹤0.01% 3194
2024
Q3 		$967 Sell
38
-103
-73% -$2.7K ﹤0.01% 3148
2024
Q2 		$3.57K Hold
141
– – ﹤0.01% 2745
2024
Q1 		$4.36K Sell
141
-90
-39% -$3.06K ﹤0.01% 2652
2023
Q4 		$9.32K Buy
+231
New +$6.94K ﹤0.01% 2280

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's BBIO Position: Q4 2025 in Review

Principal Securities sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 16 shares — an estimated $831 sold.

Principal Securities first reported a position in BBIO in Q4 2023 and held it in 8 quarters. The position peaked at $9.32K in Q4 2023. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Principal Securities reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 16 BridgeBio Pharma shares in Q4 2025, an estimated $831.
  • Principal Securities first reported a position in BridgeBio Pharma in Q4 2023 and held it in 8 quarters.
  • Principal Securities's BridgeBio Pharma position peaked at $9.32K in Q4 2023.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.